Strengths and limitations of commercial tests for hepatitis C virus RNA quantification
Morishima, C., Chung, M., Ng, KW., Brambilla, D., & Gretch, DR. (2004). Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. Journal of Clinical Microbiology, 42(1), 421-425. https://doi.org/10.1128/JCM.42.1.421-425.2004
Abstract
The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.